Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

(2013) Rakesh K. Jain   JOURNAL OF CLINICAL ONCOLOGY

Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment

(2013) A Casazza et al.   ONCOGENE

Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway

(2012) Vesselina G. Cooke et al.   CANCER CELL

Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging

(2012) T. Nielsen et al.   CLINICAL CANCER RESEARCH

Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a "Physician's Choice" Control Arm in a Randomized Approval Trial

(2012) M. Donoghue et al.   CLINICAL CANCER RESEARCH

The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

(2012) E. Pean et al.   CLINICAL CANCER RESEARCH

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

(2012) Dan M. Patterson et al.   CLINICAL CANCER RESEARCH

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

(2012) James P. B. O'Connor et al.   Nature Reviews Clinical Oncology

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Approved Agents for Metastatic Breast Cancer

(2011) Monica N. Fornier   SEMINARS IN ONCOLOGY

Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics forIn vivoEfficacy under Intermittent Dosing Conditions

(2010) Murray J. Towle et al.   CANCER RESEARCH

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Antivascular Actions of Microtubule-Binding Drugs

(2009) E. L. Schwartz   CLINICAL CANCER RESEARCH